Prerpints.org logo
Preprint
Article

Electroacupuncture Mitigates TRPV1 Overexpression in the Central Nervous System Associated with Fibromyalgia in Mice

Altmetrics

Downloads

44

Views

25

Comments

0

A peer-reviewed article of this preprint also exists.

This version is not peer-reviewed

Submitted:

04 November 2024

Posted:

07 November 2024

You are already at the latest version

Alerts
Abstract
Background: Fibromyalgia (FM) is characterized by chronic pain, significantly affecting the quality of life and functional capabilities of patients. In addition to pain, patients may experience insomnia, chronic fatigue, depression, anxiety, and headaches, further complicating their overall well-being. The Transient Receptor Potential Vanilloid 1 (TRPV1) receptor responds to various noxious stimuli and plays a key role in regulating pain sensitivity and inflammation. Thus, targeting TRPV1 may provide analgesic and anti-inflammatory benefits. This study investigates the efficacy of electroacupuncture (EA) in alleviating chronic pain in FM through TRPV1 and its downstream molecules in central nervous system (CNS). Methods: To model FM, we subjected mice to intermittent cold stress (ICS) for three days. The study comprised five rodent groups: Control, Intermitten cold stress induced FM (ICS), ICS + Electroacupuncture (EA), ICS + Sham Electroacupuncture (sham EA), and ICS + KO (TRPV1 knockout mice). Results: Our findings revealed that ICS induced allodynia and hyperalgesia in mice by day four, persisting until day 21. EA at 2 Hz and TRPV1 knockout significantly decreased both mechanical and thermal hypersensitivity (Withdrawal - Day 14: 2.43 ± 0.19 g; Day 21: 5.88 ± 0.47 g, n = 6, p < 0.05; Latency - Day 14: 2.77 ± 0.22 s; Day 21: 5.85 ± 0.41 s, n = 6, p < 0.05). In contrast, sham EA did not produce significant effects. Additionally, TRPV1 and several pain-related proteins were significantly elevated in the thalamus, somatosensory cortex (SSC), medial prefrontal cortex (mPFC), hippocampus, hypothalamus, cerebellum regions V (CB V), VI (CB VI) and VII (CB VII) after ICS model. Both EA at ST36 acupoint and TRPV1 knockout mice diminished overexpression of pain-related proteins, with the sham EA group showing no significant changes compared to the ICS group. Conclusion: Chronic widespread pain was reduced by EA and TRPV1 knockout, with the effects of EA on the TRPV1 pain pathway clearly evident in CNS after 21 days.
Keywords: 
Subject: Biology and Life Sciences  -   Behavioral Sciences

1. Introduction

Fibromyalgia (FM) is defined as a long-term disorder expressed widespread pain affecting muscles, bones, and soft tissues, typically accompanied by severe fatigue and sleep disruptions. Additional symptoms may consist of cognitive impairment referred to as “fibro fog”, depression, migraines, irritable bowel syndrome, and pain in the pelvic region, jaw, and bladder [39]. In ICD-11, FM is diagnosed under chronic widespread pain (MG30.01) and classified as a type of chronic primary pain [1]. The diagnosis of FM is based on criteria from the American College of Rheumatology, which include a widespread pain index, symptom severity reflecting weariness, poor sleep, and cognitive challenges, a minimum symptom duration of three months, and an unexplained pain origin [40]. FM symptoms can be mistaken with those of chronic fatigue syndrome, thyroid issues, or polymyalgia rheumatica, hence paraclinical tests and x-rays are employed to rule them out because FM lacks distinct diagnostic indications [39,40]. Approximately 5% of the global population was affected by FM, with the majority of cases occurring in America, Europe, and a smaller proportion in Asia [2]. The disorder primarily impacts women (1:9 ratio) and manifests any ages [3,4]. Classified as nociplastic pain, FM is characterized by a lack of definitive neuropathic attributes and an association with altered nociceptive function without clear nociceptor activation [5].
Education was believed as an initial step toward the practical goal of enhancing the life functioning for FM patients [6]. Current treatments for alleviating symptoms and improving quality of life and general wellness for patients include pharmacological and non-pharmacological approaches, which are utilized individually and progressively, based on the potential for disability and patient-specific goals [7]. Nonpharmacological interventions, including cognitive behavioral therapy, exercise, relaxing therapy, electrical stimulation, psychotherapy, meditation, massage, and acupuncture, are recommended as first-line treatments to alleviate FM [8,9]. Pharmacological treatments for FM primarily involve antidepressants such as elective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs), and anticonvulsants (pregabalin and gabapentin) [40]. The FDA has approved several drugs for fibromyalgia treatment, including pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella), classified as antiepileptics and antidepressants [37]. Acupuncture, as a non-pharmacological intervention of FM, has been shown to provide analgesic effects, reduce fatigue and anxiety, and minimize medication side effects, emphasizing the need for a clearer understanding of the pain signaling pathway mechanism [10].
Acupuncture originated in China several thousand years ago and began with the use of sharp stones and bones, now employs finely crafted, tiny needles for treatment [38]. Deqi is an essential sign of effective acupuncture, marked by sensations such as soreness, numbness, fullness, and heaviness, indicating successful activation of the meridian system. Electroacupuncture (EA) combines short-term manual acupuncture (MA) for deqi with extended EA stimulation and encompasses variations in frequency, intensity, wavelength, and duration. EA enhances somatosensory system activation and sciatic nerve blood flow more effectively than MA [11,12]. Systemic naloxone (2mg/kg) blocked EA at 2–15 Hz but not at 100 Hz, indicating that low-frequency electrical stimulation relies on the opioid system for analgesia, whereas high-frequency stimulation may utilize alternative mechanisms [13]. Professor Han firstly provided a groundbreaking explanation for the scientific mechanism of acupuncture-induced release of neurotransmitters [14]. The European League Against Rheumatism suggests acupuncture as a nonpharmacological remedy for treating FM [9]. Acupoint selection for FM in Traditional Chinese Medicine (TCM) is guided by the underlying pathophysiology. This includes patterns such as liver-spleen disharmony with symptoms of yin deficiency and empty heat, spleen and kidney yang deficiency, kidney yin and yang deficiency, rising liver fire, as well as conditions involving phlegm and wet heat [15].
Transient Receptor Potential Vanilloid 1 (TRPV1) is renowned as a ligand-gated non-selective cation channel belonging to the Transient Receptor Potential (TRP) family, which is found in both the peripheral nervous system (PNS) and the central nervous system (CNS). Harmful stimuli such as high temperature (>43 degrees Celcius), pH changes, mechanical stimulation, or permeability can activate TRPV1 expression and sending sensations of pain toward the central region [16]. TRPV1 gene-deleted mice have recently been studied for their efficacy in suppressing acute and chronic pain. TRPV1 activation triggers extensive hyperphosphorylation of downstream molecules, including phosphoinositide 3-kinases (pPI3K), protein kinase C (pPKC), and protein kinase A (pPKA), followed by mitogen-activated protein kinase (pAkt, pmTOR), mitogen-activated protein kinase (pJNK, pERK, pP38), cAMP-response element binding protein (CREB) and Nuclear factor kappa-light-chain-enhancer of activated B cells (pNF-κB). These proteins are expressed in neuronal cells, microglia, and astrocytes, which are critical for the CNS response to injury and inflammation. Wu et al. discovered that injecting capsaicin, a TRPV1 agonist, into ST36 (Zusanli) acupoints reproduced the analgesic effect observed with acupuncture [17].
This study investigates the analgesic effects of EA on FM and its underlying mechanisms via the TRPV1 pain signaling pathway. We examine TRPV1 expression and its downstream molecules in crucial brain structures, including the thalamus, somatosensory cortex (SSC), medial prefrontal cortex (mPFC), hippocampus, and cerebellum (V, VI, VII), as well as the hypothalamus. Importantly, the efficacy of sham EA and real acupuncture is compared in an animal model. By revealing these mechanisms, our research seeks to uncover innovative pain management strategies that enhance the quality of life for those suffering from FM.

2. Materials and Methods

Animal Research and Ethical Approval

The present experiments subjects were 8-12 weeks old female C57/BL6 wild type mice acquired from BioLasc Taiwan Ltd (Yilan, Taiwan), going to weigh 18-20 grams. Female TRPV1 knockout mice from Jackson Laboratory in Bar Harbor, ME, USA, were utilized for the study. Once mice were arrived, they were located in Plexiglas cages with a 12-hours alternating light and dark cycle environment, light day beginning from 6 a.m. to 6 p.m., with a normal room temperature of 25oC and humidity of 60 percent. The researchers were blind to the treatment section during the entire study.
Mice were at random assigned to one of five groups including Control mice (Con), ICS-inducted FM mice (ICS), ICS treated by EA mice (ICS+EA), ICS treated by sham EA mice (ICS+Sham EA), ICS in TRPV1 gene deletion (ICS+KO), each group consisting of six mice.
China Medical University's Institute of Animal Care and USE Committee, Taiwan approved the usage of rodents in this research (Permit number: CMUIACUC-2022-424). In this study, the welfare of the mice was prioritized to minimize their distress. All mice were handled in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.

Chronic FM Pain Induced by Intermittent Cold Stress (ICS)

This study utilized the Intermittent Cold Stress model in mice, developed by Nishiyori et al. (2008), which induces mechanical allodynia and thermal hyperalgesia lasting over 12 days and can be acutely alleviated by antidepressant treatment [18,19].
Four groups of mice were placed in a 4oC environment: ICS, ICS+EA, ICS+Sham EA, and ICS+KO, while the control group was maintained in a regular setting. At 10 a.m. the following day, these four groups were relocated to the outside environment at 25°C for 30 minutes, then back to 4°C for 30 minutes. This process was carried out until 4 p.m for a total of 6 hours, before they were repositioned again overnight from 4:30 p.m. during the first three days. After a week of acclimatization to their new environment, the mice underwent behavioral tests to determine their baseline mechanical and thermal thresholds, followed by the induction of chronic FM pain at 4:30 p.m. on day 0.

Electroacupuncture (EA) Intervention

After being anesthetized with 4% isoflurane, the mice were placed in 1% gas via the head-stuffed tube connected to the chamber. Then, a pair of 0.5-inch-long acupuncture needles (32G, Yu Kuang Chem. Ind. Corp., Taiwan) were inserted bilaterally at mice's ST36 acupoint (Zusanli). The murine ST36 was identified 3-4 mm lower than the patella, between the fibula and tibia, and on the anterior side of the anterior tibial muscle. In addition, a depth of 3-4 mm with 1 mA intensity, 2Hz frequency, and 150s width of the constant square pulse was performed for 20 minutes utilizing an electronic source from the machine (Trio 300 stimulator (Ito, Japan)) (Figure 1A,C). There was a mild twitch near the ST36 acupoint. Only the EA group applied electric current, while the sham EA group only performed sham acupuncture without electrical current. Applications of EA took place on days 15, 18, and 21, prior to the behavioral tests (Figure 1B).

Mechanical and Thermal Behavior Tests

Both tests were performed seven times on days 0, 4, 7, 10, 14, 18, and 21 at the center of the plantar of the right hind paw. Murine were enclosed in Plexiglas boxes (9.5x11x6.5 cm) above a steel mesh in a dark, noiseless, room-temperature condition to keep themselves calm and adapted to their new surroundings.
The mechanical pain threshold was evaluated using the von Frey test, where a von Frey plastic tip was gently pressed against the middle of the mouse hindpaw until the paw suddenly withdrew their paw or licked it. The pressure at that moment was recorded as the threshold value, measured in grams. When mice were not sleeping, scratching, or grooming, the von Frey test were performed three times per section, each time 10 minutes apart, to ensure the mouse did not become accustomed to the test plastic tip and tolerate the electronic von Frey filament (IITC Life Science Inc., USA).
Then, the Hargreaves’ test to measure thermal response of mice was performed. The mice were separated in various plexiglass enclosures to restrict interactions. After 30 minutes of environmental habituation, the examination began. The IITC Plantar Analgesia Meter (IITC Life, Sciences, SERIES8, Model 390G) determined the withdrawal delay of the mice foot through radiant thermal light, which was placed underneath the tempered glass and slid across the surface to the exact middle of the plantar's right hind paw. Each phase was also repeated three times for each rodent. The device was programmed to self-cut at 20 seconds to prevent harming mice's paws. The moment of foot withdrawal of mice under the impact of heat was recorded in the unit of seconds. The outcomes were collected and calculated for mean values and standard errors.

Western Blotting Experiment

After completing behavioral response evaluations, rodents were executed on day 21. Before the procedure, murine subjects were anesthetized via inhalation. In this study, we collected cerebral regions tissues across both halves of the cerebrum involving the thalamus, SSC, mPFC, hippocampus, cerebellum V, VI, VII, and hypothalamus. The tissue was immediately placed on ice and kept at -80 degrees Celsius. During the experiment, manipulations were attentively carried out to minimize their misery.
Initially, the protein homogenization was accomplished using double-distilled water, radioimmunoprecipitation (RIPA) lysis buffer (Fivephoton Biochemicals, RIPA-50), protease inhibitor (Bionovas, FC0070-0001), phosphatase inhibitor (Bionovas, FC0050-0001). Each extracted protein was electrophoretically expelled in an 8% Sodium dodecyl sulfate (SDS)-Tris-glycine gel. A current electrophoresis power supply (PowerPac, Singapore) was used to run gels before delivering the protein on gel onto the Polyvinylidene fluoride (PVDF) membrane utilizing a semi-dry transfer machine (Trans-Blot SD Cell, USA). The transferred membranes were quickly cleaned with phosphate-buffered saline Tween (PBST with 0.05% Tween 20) and blocked with Bovine Serum Albumin.
Subsequently, membranes incubated in primary antibodies (1:1000): anti-TRPV1 (~95 kDa, Alomone, ACC-030), anti-pPI3K (~130 kDa, Abcam, ab154598), anti-pAkt (~65 kDa, Thermo Fisher Scientific, 44-621G), anti-pJNK (~65 kDa, Millipore, 16-293), anti-pmTOR (~180 kDa, Millipore, 09-213), anti-pERK1/2 (~42 kDa, Abcam, ab138482), anti-pP38 (~41 kDa, Thermo Fisher Scientific, 44-684G), anti-pNF-κB (~65 kDa, Abcam, ab86299), anti-pCREB (~43 kDa, Cell Signaling Technology, 9198), anti-pPKC ( ~82 kDa, Santa Cruz Biotechnology, SC-12355), anti-pPKAII (~40 kDa, Santa Cruz Biotechnology, SC-12905), anti-tubulin (~55 kDa, Santa Cruz Biotechnology, SC-5286) in PBST containing bovine serum albumin (BSA) 1% overnight at temperature of 4oC.
After three piles of washing with PBST, secondary antibodies (1:5000) were applied to incubate with the membrane for a period of two hours at 25°C, as Peroxidase-conjugated goat anti-rabbit antibody, and goat anti-mouse antibody (Jackson Immuno Research Laboratory). The protein bands on the membranes were visualized using an enhanced chemiluminescence substrate kit (PIERCE) and by means of Celvin S (Biostep, Germany). The NIH ImageJ software (Bethesda, MD, USA) was employed to determine the image densities for certain protein bands. α-tubulin was used as internal control.

Statistical Analysis

The collected information was statistically analyzed using the Lab Origins program. All statistical data are presented as the mean ± standard error (SEM). Statistically significant differences were calculated via one-way analysis of variance (One-way ANOVA) and a post hoc Tukey’s test to determine the considerable disparity. p<0.05 was regarded as a substantial value.

3. Results

3.1. ICS-Induced Mechanical Allodynia and Thermal Hyperalgesia in Mice and Assessing the Efficacy of EA at ST36 for Chronic FM Pain

3.1.1. Von Frey Test

After performing the FM-like pain model in five groups of mice for three days, their mechnical thresholds were measured by utilzing von Frey test over 14 days to confirm chronic FM pain (Figure 2B). Figure 2A depicts the timeline describing the entire experiment on the y-axis. The withdrawal and licking responses in the middle of the right hind paw of the ICS group that received FM induction were significantly lower than those of the control group. (Figure 2A, red line, D21 = 2.5 ± 0.33 g vs. 5.91 ± 0.23 g, respectively, *p < 0.05), mechanical withdrawal threshold of ICS mice were illustrated by red line and the black line represented control mice. EA significantly mitigated the mechanical allodynia of ICS model and significantly elevated the withdrawal threshold measured by the von Frey test (Figure 2A, blue line, D21 = 5.89 ± 0.47 g, #p < 0.05 vs. ICS). Also, TRPV1 gene deletion was also indicated the attenuation of mechanical hyperalgesia (Figure 2A, pink line, D21 = 5.75 ± 0.4 g, #p < 0.05 vs. ICS). However, the sham EA cannot alter this condition after 21 days (Figure 2A, green line, D21 = 2.98 ± 0.44 g, *p < 0.05 vs. ICS).

3.1.2. Hargreaves’ Test

After the mechanical measurement, the mice were given time to rest and calm down to avoid stress. Then, the Hargreaves' test was performed to assess thermal threshold at the central of right hindpaw of mice (Figure 3B). Each application was administered three times for each mouse. The significant reduction in the hind paw withdrawal threshold in mice, measured on day 4, indicates that the ICS model induced thermal hyperalgesia (Figure 3A, red line, D0 = 5.29 ± 0.27, D4 = 2.57 ± 0.18, *p < 0.05). FM significantly depressed the heat latency threshold of ICS mice when compared to the Con group (Figure 3A, red line, D21 = 2.97 ± 0.37 s vs. lack line, 5.37 ± 0.33 s, *p < 0.05). In contrast, ICS + EA altered the thermal hyperalgesia by significantly increasing the latency threshold (Figure 3A, blue line, D21 = 5.86 ± 0.41 s, #p < 0.05 vs. ICS), which did not occur in ICS + sham EA group (Figure 3A, green line, D21 = 2.86 ± 0.21, *p < 0.05 vs. Con). Furthermore, the pink line of the ICS + KO mice shows the effect of TRPV1 gene deletion on eliciting thermal hyperalgesia (Figure 3A, pink line, D21= 6.25 ± 0.72, #p < 0.05 vs. ICS).

3.2. EA Remarkably Reduced TRPV1 and Its Downstream Pain Signaling Pathway in the CNS of FM Mice

3.2.1. The Expression of TRPV1 and Related Proteins in Thalamus and SSC

The earlier behavioral test confirmed the successful induction of chronic FM pain. Subsequently, brain samples from the ascending pain pathway were collected to assess changes in the expression of relevant proteins. The control group was established as 100% and served as a reference. Significance values were reported with the standard error of the mean (SEM), and a p-value of 0.05 was deemed statistically significant (Table 1).
Western Blot analysis revealed alterations in TRPV1 and its downstream molecules—pPKA, pPI3K, pPKC, pERK, pP38, pJNK, pAkt, pmTOR, pCREB, and pNFκB—in the thalamus and SSC of mice over a 21-day chronic study. The sensitivity of thalamus and SSC manifests similarly to the hyperalgesia and allodynia seen in the nociceptor in the peripheral region. ICS-induced FM significantly increased TRPV1 expression in thalamus and SSC of mice, while EA 2Hz effectively inhibited this overexpression after three interventions (Figure 4, n = 6, *p < 0.05, #p < 0.05). However, this attenuation had yet to be seen on these brain regions with the sham group (Figure 4, n = 6, *p < 0.05). Additionally, TRPV1 expression in KO mice was notably lower compared to the other groups (Figure 4, n = 6, *p < 0.05, #p < 0.05).
Moreover, there are evident up-regulations of pPKA, pPI3K, pPKC, pERK, pP38, pJNK, pAkt, pmTOR, pCREB, and pNFκB after ICS induction in ICS and ICS+Sham mice when compared to the Con mice in the SSC brain region (Figure 4, n = 6, *p < 0.05). EA and KO groups adversed this overexpression significantly (Figure 4, n = 6, #p < 0.05). Nevertheless, the results indicated that the expression of these proteins varied markedly among the five groups in the thalamus, similar to the findings in the SSC, except for pAkt, which showed no significant differences across any of the groups (Figure 4, n = 6).

3.2.2. TRPV1 and Its Related Proteins in mPFC and Hippocampus

The brain regions associated with the ascending pain pathway also include the mPFC and hippocampus; the Western blot results for these two regions are illustrated in Table 2. We analyzed the expression of related downstream molecules in transmitting pain signaling in mPFC including phosphorylated PKA, PI3K, and PKC, which are kinases associated with TRPV1 (Table 2). In the mPFC, chronic FM pain mice expressed a significantly higher percentage of these kinases than the Con group, and this elevation was mitigated by EA treatment at ST36 acupoints (Figure 5A, n = 6). Additionally, ICS mice showed proportion increases in pERK1/2, pP38, pJNK, and pAkt (Figure 5B, n = 6, *p < 0.05). Also, phosphorylated mTOR, CREB, NF-κB expression levels were significantly increased in ICS mice, compared to the Con group, and these upregulations were dramatically diminished by applying EA (Figure 5C, n = 6, *p < 0.05). In contrast, Sham EA cannot adversely affect the condition, while the opposite was true for the TRPV1 KO group (Figure 5A–C, n = 6, *p < 0.05, #p < 0.05).
Nonetheless, in the hippocampus, which related to both ascending and descending pain pathways, several related proteins showed no significant differences across the five subject groups, including pERK, pPKA, pPKC, pP38, pAkt, pCREB (Figure 5D–F, n = 6). On the other hand, the proportion of TRPV1, pPI3K, pJNK, pmTOR, pNF-κB in both the ICS and ICS + Sham groups showed a significant increase relative to the control group, but this rise was attenuated by EA treatment (Figure 5 D–F, n = 6). KO mice demonstrate a significant decrease in the levels of these proteins when compared to the ICS group, especially since the percentage of TRPV1 in the KO group was considerably lower than that in the Con and EA groups (Figure 5D, n = 6). This indicates that these molecules may have a location-specific function.

3.2.3. Role of TRPV1 and Related Proteins in the Descending Pathways of CBV and CBVI

We investigated the expression of several proteins in descending pain pathway. Interestingly, the analysis of pERK, pJNK, pP38, and pCREB in the cerebellar regions CBV revealed no significant differences among the research groups (Table 3). However, TRPV1 in the knockout group significant exhibited changes compared to the wild type groups (Figure 6A, n = 6). Furthermore, we observed a significant elevation in pPKA, pPI3K, pPKC, pAkt, pmTOR, pNF-κB protein after inducing FM with ICS, which was reversed by EA treatment and KO mice, but not by the Sham group (Figure 6A–C, n = 6).
In Cerebellum region VI, we identified an association between chronic sensitivity and peripheral nociceptive signaling through TRPV1 and various proteins in the pain signaling pathway, including pPI3K, pPKC, pP38, pAkt, pmTOR, pCREB, pNF-κB (Table 3). Similar to other regions, both the ICS and Sham groups exhibited a significant increase in TRPV1 level in CB VI. However, this response was reversed in the EA and TRPV1 gene deletion groups. Additionally, TRPV1 expression was present in only a small percentage compared to the wild-type mouse group (Figure 6D, n = 6).
Among the three protein kinases, pPI3K and pPKC demonstrated a similar quantitative response to TRPV1 (Figure 6D, n = 6). Additionally, the ICS model resulted in elevated expression levels of pP38, pAkt, pmTOR, pCREB, and pNF-κB (Figure 6E,F, n = 6, *p < 0.05). Both EA and TRPV1 gene deletion interventions significantly altered this activation (Figure 6D–F, n = 6, #p < 0.05). Notably, Sham EA showed no significant change in these proteins levels compared to the ICS group (Figure 6D–F, n = 6, *p < 0.05). Finally, pPKA, pERK, and pJNK exhibited no significant changes in their expression levels across the five groups (Figure 6D,E, n = 6).

3.2.4. Role of TRPV1 and Its Associated Proteins in the Descending Pathways of CBVII and the Hypothalamus

As regions linked to the descending pain pathway, CB VII and the hypothalamus play important roles in pain signaling, aligning with behavioral test results. Western Blot analysis revealed no significant changes in pPKA, pPI3K, or pPKC across the five groups in CB VII (Table 4). Similarly, pP38, pJNK, pmTOR, and pNF-κB showed no upregulation post-ICS (Table 4). However, TRPV1, pERK, pAkt, and pCREB levels were significantly altered in the ICS and Sham groups, an effect counteracted by EA treatment and TRPV1 KO (Figure 7, n = 6). In KO mice, TRPV1 expression remained notably low (Figure 7A, n = 6).
Finally, we examined the hypothalamus using Western Blot to assess TRPV1 and pain signaling protein expression across the five groups. Mirroring patterns in the thalamus, SSC, and mPFC, all proteins were upregulated after ICS induction (Figure 7, n = 6, *p < 0.05). Notably, EA and TRPV1 KO interventions significantly reversed this effect, while Sham treatment had no impact (Figure 7, n = 6). TRPV1 expression in the KO group stayed remarkably low compared to the other groups (Figure 7D, n = 6).

4. Discussion

Fibromyalgia places a significant burden on patients, negatively affecting their health, productivity, and finances. This often leaves them unable to access treatment, creating a cycle of suffering. The average annual treatment cost for FM in the United States can approach $40,000, largely due to the cost of prescribed FM medications [20]. Conversely, acupuncture in the United States is more affordable, a viable alternative for patients, and has the potential to reduce the risk of adverse effects associated with pharmaceutical interventions.
Our current investigation has examined the mechanisms of acupuncture in the ICS model. This model effectively replicates key characteristics of FM, including the induction of mechanical allodynia and thermal hyperalgesia, analogous to the heightened pain responses observed in FM patients following mild stimuli. It elicited chronic pain symptoms in ICS mice that persisted for 21 days, thereby facilitating a thorough investigation into the mechanisms underlying this disease. Furthermore, while behavioral alterations noted through forced swim tests have been referenced in prior studies, they are not addressed in this study to concentrate specifically on pain symptoms.
Research demonstrates that EA is most effective when administered early in neurological and inflammatory conditions, as it enhances recovery and improves quality of life. However, the study categorizes fibromyalgia diagnosis into early (≤2 years), late (>2-7 years), and very late (>7 years) [21]. As the diagnostic criteria require symptoms to persist for at least 3 months, early treatment or prevention of FM is challenging [22]. We verified that EA at ST36 reliably suppresses mechanical and thermal hyperalgesia in ICS mice, potentially through the TRPV1 pathway. Additionally, the EA treatment exhibited a specific effect compared to the sham group, indicating its efficacy and confirming that the observed benefits are not attributable to psychological factors or expectations. This indicates that EA is beneficial for mice with fibromyalgia and suggests the potential clinical use of supplementary treatment for fibromyalgia patients.
The brain regions targeted in this experiment are involved in both the ascending and descending pain pathways. The primary regions in the ascending pathway include the thalamus, SSC, and mPFC. The hippocampus is involved in both pathways, while the hypothalamus and cerebellum are primarily involved in the descending modulation of pain. The thalamus, located medially in the cerebrum, serves as a relay station for sensory information and is crucial for perceiving, integrating, and transmitting pain signals to the primary somatosensory cortex. The SSC comprises the primary (SI) and secondary (SII) regions. SI activity increases with more intense painful stimuli while SII is also involved in determining the source of pain [23]. mPFC plays a regulatory role in modulating pain, dampening pain-induced sympathetic activity, and mitigating facial expressions indicative of pain [24]. The hippocampus plays a crucial role in memory, emotions, and learning, indirectly influencing pain responses. The CA1 region is central to processing sensory inputs and emotional regulation, relaying this data to CA3 for the formation of chronic pain-associated memories [25]. The hypothalamus regulates pain through the HPA axis, managing stress hormone release during acute pain. In chronic pain, this axis becomes dysregulated, causing excessive cortisol production, which can lead to fatigue, depression, and impaired immune function [26]. The cerebellum primarily regulates motor control and enhances sensory processing in relation to pain. The posterior cerebellar lobes, included lobules V, VI, and VII, are involved in sensory processing and motor coordination. Lobule VI is activated by pain and thermal stimuli, while lobule VIIB processes noxious stimuli [27]. In previous inflammatory pain experiments, protein expression changes were detected in CBV and CBVII on day 3, when animals were sacrificed, with no significant changes in CBVI. In other chronic pain models (5-8 days), notable protein alterations were found in the SSC, mPFC, hippocampus, and posterior cerebellum.
In the current experiment, we applied ICS to induce chronic pain lasting up to 3 weeks in mice, as opposed to continuous cold stress that only produces acute pain. This model meets the criteria of the diagnostic standard [A]. Behavioral assessments showed a significant reduction in mechanical withdrawal threshold and thermal withdrawal latency after just 4 days, persisting until day 21, compared to the control group. Immunoblotting results supported this finding, revealing distinct changes during the chronic phase across studied brain regions. Areas primarily involved in pain processing, including the thalamus, SSC, and mPFC, showed a marked increase in all proteins percentage in the ICS group compared to controls. Conversely, the hippocampus exhibited changes in the density of TRPV1, pPI3K, pJNK, pmTOR, and pNF-κB and cerebellum V in TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pNF-κB density, while the cerebellum VI displayed no alterations in pPKA, pERK, and pJNK proportion and cerebellum VII in pPKA, pPI3K, pPKC, pP38, pJNK, pmTOR, pNF-κB percentage. Specifically, the hypothalamus, although not a primary pain signaling center, also exhibited alterations in all assessed proteins.
TRPV1 and μ-opioid receptors are involved in the regulation of β-arrestin 2 to regulate inflammatory responses [28]. Therefore, treatments targeting both the μ-opioid and the TRPV1 receptors are believed to be beneficial in eliminating pain and preventing opioid addiction [28]. EA reduces the expression of glial cells marker in the PNS and CNS. EA increases adenosine levels while decreasing substance P and inflammatory agents such as IL-1, IL-6, and TNF-α at the ST36 acupoint [29]. Similarly, EA modulated Nav1.8, COX-2, and pPKCε in animal models via adenosine correction [30]. The pain signaling pathway of kinases PI3K/Akt plays a crucial role in modulate the pain through the affection to mediated inflammator and reducing cytokines such as TNF-α and IL-17 [31]. EA inhibited the phosphorylation of PI3K and Akt, which activating the inflamatory, to reduce the hyperalgesia in mice injected Carrageenan [32] . TRPV1 can stimulate anandamide (AEA) synthesis [33], which in turn activates PKC [29]. Flow cytometry experiments have revealed that pERK, p38, and pJNK are co-phosphorylated after proinflammatory injection, implying a role in pain signaling [34]. Our findings suggest that pJNK and pP38 have been associated with increased sensitivity to toxic stimuli in chronic pain. cAMP (PKA) increases intracellular calcium transients through phosphorylation, triggers neuronal sensitization. Activated PKA (pPKA) can activate various ion channels, including voltage-gated calcium channels such as TRPV1 and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. The activation of these channels facilitates calcium influx into the cell, either directly or indirectly, by promoting the opening of calcium channels, thereby increasing intracellular calcium levels [35]. The PKA/CREB signaling pathway is closely associated with the mechanisms underlying inflammatory pain.
Our data demonstrated elevated TRPV1 expression and its associated proteins in the thalamus, SSC, mPFC, hippocampus, CB V, VI, VII, and hypothalamus of mice, which was reduced by EA treatment and in TRPV1 KO mice. Previous studies indicate that these brain regions are linked to pain signaling through elevated expression of TRPV1 and other proteins over five days in the model. TRPV1 contributes to both long-term potentiation (LTP) and long-term depression (LTD) at excitatory synapses in the hippocampal dentate gyrus [36].
This study examined protein expression in eight brain regions using Western blot analysis, providing observational data. The results eliminated the placebo effect by employing a sham EA group without de-qi sensation. Deletion of the TRPV1 gene in mice results in the absence of physical hypersensitivity. Further investigation is needed, particularly focusing on brain regions to determine protein localization. Additionally, its relevance to clinical application remains unaddressed.

5. Conclusions

In summary, our findings demonstrate that EA effectively alleviates mechanical and thermal hypersensitivity associated with long-term pain. This heightened sensitivity to noxious stimuli is associated with the role of TRPV1 and its downstream signaling molecules in the CNS. Notably, the presence of TRPV1 and associated pain signaling pathways contributes to central sensitization in brain regions, including the thalamus, SSC, mPFC, hippocampus, CB V, VI, VII, and hypothalamus.

Author Contributions

DTNA performed the experiments, analyzed and interpreted the data, and wrote the draft manuscript. YWL revised and submitted the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Funding

This work was supported by the following grants: NSTC 113-2314-B-039-047, CMU113-MF-87, and the “Chinese Medicine Research Center, China Medical University” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

Institutional Review Board Statement

China Medical University's Institute of Animal Care and USE Committee, Taiwan approved the usage of rodents in this research (Permit number: CMUIACUC-2022-424).

Acknowledgments

The authors would like to thank Enago (www.enago.tw) for the English language review.

Conflicts of Interest

The authors declare no conflict of interest.on to publish the results.

References

  1. Barke, A.; Korwisi, B.; Rief, W. Chronic pain in the ICD-11: New diagnoses that clinical psychologists should know about. Clin. Psychol. Eur. 2022, 4, e9933. [Google Scholar] [CrossRef] [PubMed]
  2. Ruschak, I.; Montesó-Curto, P.; Rosselló, L.; Aguilar Martín, C.; Sánchez-Montesó, L.; Toussaint, L. Fibromyalgia Syndrome Pain in Men and Women: A Scoping Review. Healthcare 2023, 11, 223. [Google Scholar] [CrossRef] [PubMed]
  3. Cronan, T.A.; Serber, E.R.; Walen, H.R.; Jaffe, M. The Influence of Age on Fibromyalgia Symptoms. J. Aging Health. 2002, 14, 370–384. [Google Scholar] [CrossRef] [PubMed]
  4. Bartels, E.M.; Dreyer, L.; Jacobsen, S.; Jespersen, A.; Bliddal, H.; Danneskiold-Samsøe, B. Fibromyalgia, Diagnosis and Prevalence: Are Gender Differences Explainable? Ugeskr. Læger. 2009, 171, 3588–3592. [Google Scholar]
  5. Kosek, E.; Cohen, M.; Baron, R.; Gebhart, G.F.; Mico, J.A.; Rice, A.S.C.; Rief, W.; Sluka, A.K. Do We Need a Third Mechanistic Descriptor for Chronic Pain States? Pain. 2016, 157, 1382–1386. [Google Scholar] [CrossRef]
  6. Häuser, W.; Fisher, E.; Perrot, S.; Moore, R.A.; Makri, S.; Bidonde, J. Non-pharmacological interventions for fibromyalgia (fibromyalgia syndrome) in adults: An overview of Cochrane Reviews. CDSR 2022, 2022, CD015074. [Google Scholar] [CrossRef]
  7. Pinto, A.M.; Geenen, R.; Castilho, P.; da Silva, J.A.P. Progress towards improved non-pharmacological management of fibromyalgia. Joint Bone Spine. 2020, 87, 377–379. [Google Scholar] [CrossRef]
  8. Hernando-Garijo, I.; Jiménez-Del-Barrio, S.; Mingo-Gómez, T.; Medrano-de-la-Fuente, R.; Ceballos-Laita, L. Effectiveness of non-pharmacological conservative therapies in adults with fibromyalgia: A systematic review of high-quality clinical trials. J Back Musculoskelet Rehabil. 2022, 35, 3–20. [Google Scholar] [CrossRef]
  9. Macfarlane, G.J.; Kronisch, C.; Dean, L.E.; Atzeni, F.; Häuser, W.; Fluß, E.; Choy, E.; Kosek, E.; Amris, K.; Branco, J.; et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017, 76, 318–328. [Google Scholar] [CrossRef]
  10. Martin, D.P.; Sletten, C.D.; Williams, B.A.; Berger, I.H. Improvement in fibromyalgia symptoms with acupuncture: Results of a randomized controlled trial. Mayo Clin. Proc. 2006, 81, 749–757. [Google Scholar] [CrossRef]
  11. Napadow, V.; Makris, N.; Liu, J.; Kettner, N.W.; Kwong, K.K.; Hui, K.K. Effects of electroacupuncture versus manual acupuncture on the human brain as measured by fMRI. Hum Brain Mapp. 2005, 24, 193–205. [Google Scholar] [CrossRef] [PubMed]
  12. Inoue, M.; Hojo, T.; Nakajima, M.; Kitakoji, H.; Itoi, M.; Katsumi, Y. The effect of electrical stimulation of the pudendal nerve on sciatic nerve blood flow in animals. Acupunct Med. 2008, 26, 145–148. [Google Scholar] [CrossRef] [PubMed]
  13. Wang, J.Q.; Mao, L.; Han, J.S. Comparison of the antinociceptive effects induced by electroacupuncture and transcutaneous electrical nerve stimulation in the rat. Int J Neurosci. 1992, 65, 117–129. [Google Scholar] [CrossRef] [PubMed]
  14. Han, J.S.; Terenius, L. Neurochemical basis of acupuncture analgesia. Annu. Rev. Pharmacol. Toxicol. 1982, 22, 193–220. [Google Scholar] [CrossRef] [PubMed]
  15. Vas, J.; Modesto, M.; Aguilar, I.; Santos-Rey, K.; Benítez-Parejo, N.; Rivas-Ruiz, F. Effects of acupuncture on patients with fibromyalgia: Study protocol of a multicentre randomized controlled trial. Trials. 2011, 12, 59. [Google Scholar] [CrossRef]
  16. Jara-Oseguera, A.; Simon, S.A.; Rosenbaum, T. TRPV1: On the road to pain relief. Curr. Mol. Pharmacol. 2008, 1, 255–269. [Google Scholar] [CrossRef]
  17. Wu, S.Y.; Chen, W.H.; Hsieh, C.L.; Lin, Y.W. Abundant expression and functional participation of TRPV1 at Zusanli acupoint (ST36) in mice: Mechanosensitive TRPV1 as an "acupuncture-responding channel". BMC Complement Altern Med. 2014, 14, 96. [Google Scholar] [CrossRef]
  18. Nishiyori, M.; Ueda, H. Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia. Mol Pain. 2008, 4, 52. [Google Scholar] [CrossRef]
  19. Nishiyori, M.; Uchida, H.; Nagai, J.; Araki, K.; Mukae, T.; Kishioka, S.; Ueda, H. Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants. Mol Pain. 2011, 7, 69. [Google Scholar] [CrossRef]
  20. D'Onghia, M.; Ciaffi, J.; Ruscitti, P.; Cipriani, P.; Giacomelli, R.; Ablin, J.N.; Ursini, F. The economic burden of fibromyalgia: A systematic literature review. Semin Arthritis Rheum. 2022, 56, 152060. [Google Scholar] [CrossRef]
  21. Moshrif, A.; Mosallam, A.; Abu-Zaid, M.H.; Gouda, W. Evaluating the effect of delayed diagnosis on disease outcome in fibromyalgia: A multi-center cross-sectional study. J Pain Res. 2023, 16, 1355–1365. [Google Scholar] [CrossRef] [PubMed]
  22. Wolfe, F.; Clauw, D.J.; Fitzcharles, M.A.; Goldenberg, D.L.; Häuser, W.; Katz, R.L.; Mease, P.J.; Russell, A.S.; Russell, I.J.; Walitt, B. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016, 46, 319–329. [Google Scholar] [CrossRef] [PubMed]
  23. Kropf, E.; Syan, S.K.; Minuzzi, L.; Frey, B.N. From anatomy to function: The role of the somatosensory cortex in emotional regulation. Braz J Psychiatry. 2019, 41, 261–269. [Google Scholar] [CrossRef]
  24. Ong, W.Y.; Stohler, C.S.; Herr, D.R. Role of the prefrontal cortex in pain processing. Mol Neurobiol. 2019, 56, 1137–1166. [Google Scholar] [CrossRef] [PubMed]
  25. Zhao, X.Y.; Liu, M.G.; Yuan, D.L.; Wang, Y.; He, Y.; Wang, D.D.; Chen, X.F.; Zhang, F.K.; Li, H.; He, X.S.; et al. Nociception-induced spatial and temporal plasticity of synaptic connection and function in the hippocampal formation of rats: A multi-electrode array recording. Mol Pain. 2009, 5, 55. [Google Scholar] [CrossRef]
  26. Nees, F.; Löffler, M.; Usai, K.; Flor, H. Hypothalamic-pituitary-adrenal axis feedback sensitivity in different states of back pain. Psychoneuroendocrinology. 2019, 101, 60–66. [Google Scholar] [CrossRef]
  27. Moulton, E.A.; Schmahmann, J.D.; Becerra, L.; Borsook, D. The cerebellum and pain: Passive integrator or active participator? Brain Res Rev. 2010, 65, 14–27. [Google Scholar] [CrossRef]
  28. Wang, X.; Bao, C.; Li, Z.; Yue, L.; Hu, L. Side Effects of Opioids Are Ameliorated by Regulating TRPV1 Receptors. Int. J. Environ. Res. Public Health. 2022, 19, 2387. [Google Scholar] [CrossRef]
  29. Puntambekar, P.; Van Buren, J.; Raisinghani, M.; Premkumar, L.S.; Ramkumar, V. Direct interaction of adenosine with the TRPV1 channel protein. J Neurosci. 2004, 24, 3663–3671. [Google Scholar] [CrossRef]
  30. Zhang, R.Y.; Zhu, B.F.; Wang, L.K.; Song, Y.; Zhao, J.G.; Guo, Y.; Zhao, L.; Chen, S. Electroacupuncture alleviates inflammatory pain via adenosine suppression and its mediated substance P expression. Arq Neuropsiquiatr. 2020, 78, 617–623. [Google Scholar] [CrossRef]
  31. Fu, X.; Zhang, Y.; Zhang, R. Regulatory role of the PI3K/Akt/WNK1 signaling pathway in a mouse model of bone cancer pain. Sci Rep. 2023, 13, 14321. [Google Scholar] [CrossRef]
  32. Kim, H.N.; Kim, Y.R.; Jang, J.Y.; Shin, H.K.; Choi, B.T. Electroacupuncture inhibits phosphorylation of spinal phosphatidylinositol 3-kinase/Akt in a carrageenan-induced inflammatory rat model. Brain Res Bull. 2012, 87, 199–204. [Google Scholar] [CrossRef] [PubMed]
  33. Ferrer Montiel, A.; García-Martínez, C.; Morenilla, C.; García-Sanz, N.; Fernández-Carvajal, A.; Fernandez-Ballester, G.; Planells-Cases, R. Molecular architecture of the vanilloid receptor: Insights for drug design. Eur J Biochem. 2004, 271, 1820–1826. [Google Scholar] [CrossRef] [PubMed]
  34. Manjavachi, M.N.; Motta, E.M.; Marotta, D.M.; Leite, D.F.P.; Calixto, J.B. Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Pain. 2010, 151, 345–355. [Google Scholar] [CrossRef] [PubMed]
  35. Herrmann, S.; Rajab, H.; Christ, I.; Schirdewahn, C.; Höfler, D.; Fischer, M.J.; Bruno, A.; Fenske, S.; Gruner, C.; Kramer, F.; et al. Protein kinase A regulates inflammatory pain sensitization by modulating HCN2 channel activity in nociceptive sensory neurons. Pain. 2017, 158, 2012–2024. [Google Scholar] [CrossRef]
  36. Puente, N.; Reguero, L.; Elezgarai, I.; Canduela, M.J.; Mendizabal-Zubiaga, J.; Ramos-Uriarte, A.; Fernández-Espejo, E.; Grandes, P. The transient receptor potential vanilloid-1 is localized at excitatory synapses in the mouse dentate gyrus. Brain Struct Funct. 2015, 220, 1187–1194. [Google Scholar] [CrossRef]
  37. Forte, M.L.; Butler, M.; Andrade, K.E.; et al. Treatments for Fibromyalgia in Adult Subgroups [Internet]; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2015 Jan. (Comparative Effectiveness Reviews, No. 148); Table 1, FDA-approved drugs for the treatment of fibromyalgia. Available from: https://www.ncbi.nlm.nih.gov/books/NBK274463/table/introduction.t1/.
  38. White, A.; Ernst, E. A brief history of acupuncture. Rheumatology 2004, 43, 662–663. [Google Scholar] [CrossRef]
  39. Fibromyalgia. (n.d.). Available online: https://rheumatology.org/patients/fibromyalgia.
  40. Bhargava, J.; Hurley, J.A. Fibromyalgia. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, 2024 Jan-. Last updated: June 11, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK540974/.
Preprints 138489 g001
Figure 1. Application of bilateral electroacupuncture (EA) at 2 Hz on the ST36 (Zusanli) acupoint in FM mice. (A) Anatomical location of ST36 in mice. (B) Timeline of EA administration on days 15, 18, and 21. (C) Electric stimulation protocol used in the ICS+EA group.
Figure 1. Application of bilateral electroacupuncture (EA) at 2 Hz on the ST36 (Zusanli) acupoint in FM mice. (A) Anatomical location of ST36 in mice. (B) Timeline of EA administration on days 15, 18, and 21. (C) Electric stimulation protocol used in the ICS+EA group.
Preprints 138489 g001
Preprints 138489 g002
Figure 2. This diagram depicts the mechanical threshold of mice in five groups. (A) von Frey test measured the withdrawal threshold (gram = g), (B) The figure depicts the process involved in the mechanical test. The study involved five groups: Control (Con), Intermittent Cold Stress-induced Fibromyalgia-like pain (ICS), ICS + Electroacupuncture (ICS + EA), ICS + Sham EA (ICS + Sham), and ICS + TRPV1 knockout (ICS + KO). The ICS model was applied during the first three days (ICS d0, d3), and EA was administered on days 15, 18, and 21, prior to the von Frey test. Each mouse was measured three times, with 10-minute intervals between measurements.* Denotes a significant difference in comparison to the Control group. # denotes significant differences with the ICS group.
Figure 2. This diagram depicts the mechanical threshold of mice in five groups. (A) von Frey test measured the withdrawal threshold (gram = g), (B) The figure depicts the process involved in the mechanical test. The study involved five groups: Control (Con), Intermittent Cold Stress-induced Fibromyalgia-like pain (ICS), ICS + Electroacupuncture (ICS + EA), ICS + Sham EA (ICS + Sham), and ICS + TRPV1 knockout (ICS + KO). The ICS model was applied during the first three days (ICS d0, d3), and EA was administered on days 15, 18, and 21, prior to the von Frey test. Each mouse was measured three times, with 10-minute intervals between measurements.* Denotes a significant difference in comparison to the Control group. # denotes significant differences with the ICS group.
Preprints 138489 g002
Preprints 138489 g003
Figure 3. This diagram illustrates the thermal sensitivity of mice across five groups. (A) The withdrawal threshold was assessed using the Hargreaves test (second = s), (B) The figure illustrates the procedure of the thermal test. The study involved five groups: Control (Con), Intermittent Cold Stress-induced Fibromyalgia-like pain (ICS), ICS + Electroacupuncture (ICS + EA), ICS + Sham EA (ICS + Sham), and ICS + TRPV1 knockout (ICS + KO). The Intermitten cold stress (ICS) model was applied during the first three days (ICS d0, d3), and EA was administered on days 15, 18, and 21 (EA d15, d18, d21), prior to the von Frey test. Each mouse was measured three times, with 10-minute intervals between measurements.* Denotes a significant difference in comparison to the Control group. # denotes significant differences with the ICS group.
Figure 3. This diagram illustrates the thermal sensitivity of mice across five groups. (A) The withdrawal threshold was assessed using the Hargreaves test (second = s), (B) The figure illustrates the procedure of the thermal test. The study involved five groups: Control (Con), Intermittent Cold Stress-induced Fibromyalgia-like pain (ICS), ICS + Electroacupuncture (ICS + EA), ICS + Sham EA (ICS + Sham), and ICS + TRPV1 knockout (ICS + KO). The Intermitten cold stress (ICS) model was applied during the first three days (ICS d0, d3), and EA was administered on days 15, 18, and 21 (EA d15, d18, d21), prior to the von Frey test. Each mouse was measured three times, with 10-minute intervals between measurements.* Denotes a significant difference in comparison to the Control group. # denotes significant differences with the ICS group.
Preprints 138489 g003
Preprints 138489 g004
Figure 4. Percentage changes in TRPV1 and associated molecules in the thalamus and SSC of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Figure 4. Percentage changes in TRPV1 and associated molecules in the thalamus and SSC of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Preprints 138489 g004
Preprints 138489 g005
Figure 5. Percentage changes in TRPV1 and associated molecules in the mPFC and hippocampus of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Figure 5. Percentage changes in TRPV1 and associated molecules in the mPFC and hippocampus of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Preprints 138489 g005
Preprints 138489 g006
Figure 6. Percentage changes in TRPV1 and associated molecules in the CBV and CBVI of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Figure 6. Percentage changes in TRPV1 and associated molecules in the CBV and CBVI of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Preprints 138489 g006
Preprints 138489 g007
Figure 7. Percentage changes in TRPV1 and associated molecules in the CB VII and hypothalamus of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Figure 7. Percentage changes in TRPV1 and associated molecules in the CB VII and hypothalamus of mice. The Western blotting analysis included five lanes for each protein: Con, ICS, ICS + EA, ICS + Sham, and ICS + KO. The proteins observed were TRPV1, pPKA, pPI3K, pPKC, pAkt, pmTOR, pERK, pP38, pJNK, pCREB, and pNF-κB. Asterisks (*) indicate significant differences between the Con group and the other groups, while hash symbols (#) denote significant differences between the ICS and the other groups. n = 6.
Preprints 138489 g007
Table 1. 2Hz EA at the Zusanli acupoint significantly suppresses the overexpression of TRPV1 and its associated downstream molecules in the thalamus and SSC after ICS-induced FM. Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli, ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNFκB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Table 1. 2Hz EA at the Zusanli acupoint significantly suppresses the overexpression of TRPV1 and its associated downstream molecules in the thalamus and SSC after ICS-induced FM. Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli, ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNFκB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Brain region Protein Con ICS ICS + EA ICS + Sham ICS + KO
Thalamus TRPV1 102.15 ± 1.89 157.86 ± 6.97* 105.93 ± 3.88# 152.95 ± 6.07* 16.36 ± 1.95*#
pPKA 100.08 ± 0.27 150.35 ± 6.62* 104.55 ± 2.21# 146.65 ± 4.52* 103.78 ± 3.22#
pPI3K 99.6 ± 0.29 146.81 ± 5.05* 102.15 ± 4.99# 146.03 ± 4.89* 103.93 ± 1.75#
pPKC 99.23 ± 0.57 161.5 ± 4.17* 101.8 ± 2.01# 160.85 ± 5.11* 98.98 ± 3.92#
pERK 99.83 ± 0.39 171.5 ± 5.47* 104.63 ± 5.52# 161.46 ± 5.63* 88.85 ± 7.54#
pP38 99.96 ± 0.09 138.4 ± 3.43* 100.45 ± 3.15# 134.06 ± 3.53* 87.35 ± 5.57#
pJNK 99.93 ± 0.26 161.23 ± 7.35* 103.16 ± 1.40# 161.45 ± 6.88* 99.38 ± 1.66#
pAkt 99.99 ± 0.1 98.21 ± 1.07 99.89 ± 2.89 98.28 ± 1.81 96.27 ± 2.46
pmTOR 99.25 ± 0.79 159.91 ± 8.01* 109.08 ± 3.84# 161.1 ± 6.55* 107.98 ± 4.24#
pCREB 100.3 ± 0.47 155.05 ± 6.04* 109.26 ± 2.99# 155.58 ± 7.33* 99.46 ± 5.18#
pNF-κB 100.2 ± 0.21 150.11 ± 5.26* 100.36 ± 2.46# 147.85 ± 7.26* 100.2 ± 3.07#
SSC TRPV1 100.35 ± 0.48 158.3 ± 2.74* 97.05 ± 5.40# 144.61 ± 6.07* 15.66 ± 2.37*#
pPKA 99.93 ± 0.02 137.63 ± 4.33* 105.65 ± 3.51# 136.2 ± 5.64* 89.08 ± 5.16#
pPI3K 99.85 ± 0.73 144.58 ± 3.20* 104.41 ± 5.29# 143.13 ± 4.12* 84.93 ± 5.33#
pPKC 101.1 ± 1.13 147.81 ± 4.85* 114.28 ± 3.54# 143.05 ± 5.99* 103.31 ± 4.45#
pERK 100.05 ± 0.02 154.83 ± 4.58* 111.31 ± 3.22# 160.88 ± 11.01* 102.7 ± 10.15#
pP38 99.18 ± 0.94 137.93 ± 3.39* 107.58 ± 2.18# 139.9 ± 2.84* 104.28 ± 5.28#
pJNK 99.85 ± 0.21 129.01 ± 1.38* 102.68 ± 2.24# 127.35 ± 3.50* 101.58 ± 6.80#
pAkt 100.33 ± 0.36 137.23 ± 4.43* 108.25 ± 2.20# 132.66 ± 3.00* 100.51 ± 4.24#
pmTOR 99.45 ± 0.37 148.33 ± 5.58* 104.78 ± 7.55# 144.55 ± 7.60* 103.71 ± 9.28#
pCREB 99.66 ± 0.26 151.1 ± 3.05* 109.63 ± 4.50# 150.9 ± 4.76* 94.28 ± 5.82#
pNF-κB 99.51 ± 0.11 136.95 ± 5.31* 105.93 ± 3.71# 133.23 ± 4.97* 104.2 ± 3.71#
Table 2. The table shows data on the increase of TRPV1, pPKA, pPI3K, pPKC, pERK, pP38, pJNK, pAkt, pmTOR, pCREB, and pNFκB after applying ICS in the mPFC and hippocampus of mice. Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli (ST36), ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNF-κB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Table 2. The table shows data on the increase of TRPV1, pPKA, pPI3K, pPKC, pERK, pP38, pJNK, pAkt, pmTOR, pCREB, and pNFκB after applying ICS in the mPFC and hippocampus of mice. Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli (ST36), ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNF-κB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Brain region Protein Con ICS ICS + EA ICS + Sham ICS + KO
mPFC TRPV1 100.1 ± 0.67 160.7 ± 4.97* 103.86 ± 2.27# 161.23 ± 8.32* 7.76 ± 1.83*#
pPKA 100.05 ± 0.21 155.01 ± 2.92* 104.98 ± 5.93# 145.48 ± 5.29* 103.36 ± 4.87#
pPI3K 99.88 ± 0.17 141.9 ± 5.20* 95.23 ± 4.23# 143.36 ± 5.24* 99.28 ± 2.39#
pPKC 99.83 ± 0.12 151.26 ± 2.86* 96.85 ± 8.43# 146.53 ± 6.26* 97.03 ± 4.53#
pERK 100.21 ± 0.15 150.43 ± 6.95* 100.06 ± 4.13# 139.71 ± 3.91* 79.58 ± 7.68#
pP38 99.96 ± 0.08 147.21 ± 3.82* 103.76 ± 3.53# 151 ± 3.45* 99.36 ± 2.99#
pJNK 100.35 ± 0.36 158.16 ± 4.40* 106.43 ± 4.76# 150.3 ± 6.06* 99.43 ± 3.18#
pAkt 100.03 ± 0.26 164.43 ± 3.10* 111.26 ± 3.38# 158.01 ± 3.88* 106.21 ± 3.55#
pmTOR 100.03 ± 0.55 154.98 ± 5.50* 101.8 ± 4.39# 161.55 ± 5.82* 98.1 ± 2.73#
pCREB 99.88 ± 0.24 162.76 ± 6.06* 112.65 ± 4.11# 166.33 ± 3.20* 103.65 ± 5.40#
pNF-κB 99.85 ± 0.26 175.91 ± 3.40* 103.48 ± 4.86# 172.95 ± 6.59* 88.71 ± 3.61#
Hippo TRPV1 99.48 ± 0.62 136.30 ± 4.76* 100.17 ± 3.05# 137.92 ± 5.22* 24.26 ± 1.46*#
pPKA 99.91 ± 0.21 99.52 ± 5.92 108.47 ± 9.40 97.59 ± 2.25 96.79 ± 4.95
pPI3K 100.04 ± 0.23 133.89 ± 9.05* 97.83 ± 0.41# 132.04 ± 5.01* 97.28 ± 2.88#
pPKC 99.82 ± 0.19 91.78 ± 2.36 107.74 ± 9.82 96.65 ± 4.74 104.09 ± 5.75
pERK 100.1 ± 0.17 94.84 ± 2.59 98.72 ± 8.06 94.98 ± 7.46 89.71 ± 5.66
pP38 99.71 ± 0.10 101.03 ± 5.53 97.75 ± 3.40 99.9 ± 3.30 89.29 ± 3.74
pJNK 99.94 ± 0.31 130.89 ± 2.32* 102.96 ± 1.46# 129.86 ± 3.90* 105.41 ± 1.25#
pAkt 100.01 ± 0.14 100.31 ± 7.46 99.98 ± 6.39 103.21 ± 8.92 102.95 ± 4.34
pmTOR 100.22 ± 0.14 144.94 ± 7.76* 102.91 ± 3.18# 148.85 ± 8.09* 103.37 ± 2.19#
pCREB 100.11 ± 0.14 95.32 ± 9.37 101.34 ± 4.78 105.71 ± 5.42 101.24 ± 8.67
pNF-κB 99.73 ± 0.07 125.95 ± 4.22* 96.58 ± 4.34# 122.40 ± 3.17* 97.44 ± 5.67#
Table 3. Statistical data demonstrated the expression levels of TRPV1 and its associated downstream molecules across five groups of mice in cerebellum V and VI (CBV, VI). Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli, ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNF-κB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Table 3. Statistical data demonstrated the expression levels of TRPV1 and its associated downstream molecules across five groups of mice in cerebellum V and VI (CBV, VI). Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli, ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNF-κB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Brain region Protein Con ICS ICS + EA ICS + Sham ICS + KO
CBV TRPV1 99.55 ± 0.63 155.29 ± 7.73* 100.27 ± 3.01# 151.11 ± 8.42* 26.15 ± 1.14*#
pPKA 100.13 ± 0.18 157.92 ± 5.49* 110.42 ± 6.45# 170.84 ± 12.04* 99.08 ± 13.15#
pPI3K 100.06 ± 0.14 149.3 ± 13.09* 99.40 ± 2.94# 144.25 ± 4.19* 87.76 ± 7.18#
pPKC 100.16 ± 0.20 128.77 ± 4.81* 103.73 ± 4.51# 123.02 ± 4.37* 101.65 ± 2.64#
pERK 100.15 ± 0.14 91.12 ± 19.02 60.59 ± 26.65 55.53 ± 16.47 61.16 ± 9.71
pP38 100.02 ± 0.05 101.72 ± 2.37 100.43 ± 4.01 103.72 ± 4.75 99.41 ± 8.32
pJNK 99.91 ± 0.16 114.17 ± 14.68 115.47 ± 16.12 111.28 ± 7.17 101.21 ± 8.90
pAkt 100.01 ± 0.10 125.44 ± 3.65* 86.69 ± 5.20# 125.10 ± 5.47* 83.84 ± 7.89#
pmTOR 100.39 ± 0.59 159.69 ± 3.63* 97.58 ± 6.11# 139.32 ± 8.01* 86.21 ± 16.80#
pCREB 100.03 ± 0.20 109.93 ± 3.81 97.09 ± 9.79 107.53 ± 6.11 107.99 ± 7.97
pNF-κB 99.59 ± 0.23 155.50 ± 5.07* 110.66 ± 6.02# 146.87 ± 9.93* 105.09 ± 9.37#
CBVI TRPV1 100.51 ± 0.32 136.53 ± 1.39* 102.45 ± 3.80# 140.47 ± 3.97* 27.01 ± 1.33*#
pPKA 100.26 ± 0.08 107.88 ± 2.62 106.86 ± 6.79 104.00 ± 5.16 94.94 ± 7.84
pPI3K 100.25 ± 0.29 138.62 ± 8.61* 111.33 ± 6.13# 137.87 ± 8.27* 94.62 ± 4.96#
pPKC 100.16 ± 0.17 135.61 ± 4.22* 104.09 ± 5.54# 128.54 ± 8.08* 92.71 ± 6.45#
pERK 100.00 ± 0.11 96.98 ± 8.55 83.15 ± 21.57 89.87 ± 15.50 83.60 ± 13.75
pP38 100.31 ± 0.41 150.73 ± 2.27* 117.84 ± 6.24# 145.31 ± 7.01* 88.91 ± 10.01#
pJNK 99.92 ± 0.11 113.02 ± 9.09 104.24 ± 6.54 109.31 ± 3.45 103.61 ± 4.41
pAkt 99.77 ± 0.28 139.54 ± 1.07* 105.03 ± 0.76# 133.46 ± 3.68* 94.61 ± 2.25#
pmTOR 100.27 ± 0.45 152.34 ± 11.70* 112.65 ± 6.11# 145.04 ± 8.41* 91.17 ± 6.05#
pCREB 99.65 ± 0.17 139.49 ± 7.90* 108.45 ± 3.28# 137.89 ± 7.68 80.43 ± 9.71#
pNF-κB 99.51 ± 0.30 131.25 ± 3.13* 101.24 ± 1.64# 129.16 ± 4.32* 100.84 ± 4.26#
Table 4. Western blot data were analyzed showing an increase in pain signaling proteins in CB VII and hypothalamus (Hypo) under intermittent cold stress and the effect of EA in mitigating hyperalgesia consistent with the results of behavioral tests. Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli, ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNF-κB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Table 4. Western blot data were analyzed showing an increase in pain signaling proteins in CB VII and hypothalamus (Hypo) under intermittent cold stress and the effect of EA in mitigating hyperalgesia consistent with the results of behavioral tests. Con: Control, ICS: Intermittent Cold Stress-induced FM, ICS+EA: Electroacupuncture 2Hz at the Zusanli, ICS+Sham: Sham EA, ICS+KO: Transient Receptor Potential Vanilloid 1 knockout gene. TRPV1: Transient Receptor Potential Vanilloid 1, pPKA:phosphorylated Protein Kinase A, pPI3K:phosphorylated Phosphoinositide 3-Kinase, pPKC: phosphorylated Protein Kinase C, pERK: phosphorylated Extracellular Signal-Regulated Kinase, pP38: phosphorylated P38 Mitogen-Activated Protein Kinase, pJNK: phosphorylated c-Jun N-terminal Kinase, pAkt: phosphorylated Protein Kinase B (Akt), pmTOR: phosphorylated Mechanistic Target of Rapamycin, pCREB: phosphorylated cAMP Response Element-Binding Protein, pNF-κB: phosphorylated Nuclear Factor Kappa B. *p < 0.05 vs. Con, #p < 0.05 vs. ICS.
Brain region Protein Con ICS ICS + EA ICS + Sham ICS + KO
CB VII TRPV1 99.93 ± 0.17 141.34 ± 5.88* 102.52 ± 2.45# 139.48 ± 6.30* 25.09 ± 0.60*#
pPKA 100.33 ± 0.11 99.76 ± 1.77 93.21 ± 2.25 101.93 ± 3.98 89.06 ± 9.31
pPI3K 99.85 ± 0.13 107.94 ± 2.46 110.17 ± 6.51 102.75 ± 5.24 103.7 ± 5.14
pPKC 99.92 ± 0.15 102.53 ± 6.12 95.54 ± 5.30 104.14 ± 7.19 107.17 ± 10.55
pERK 100.38 ± 0.20 144.46 ± 5.72* 104.02 ± 2.33# 140.84 ± 9.87* 95.25 ± 4.09#
pP38 100.10 ± 0.09 105.01 ± 5.06 104.11 ± 4.47 105.45 ± 8.43 101.31 ± 8.36
pJNK 100.08 ± 0.07 105.15 ± 2.68 102.04 ± 3.59 107.55 ± 4.53 99.83 ± 6.21
pAkt 100.48 ± 0.12 145.28 ± 4.80* 100.46 ± 3.19# 138.80 ± 5.83* 95.67 ± 7.27#
pmTOR 99.98 ± 0.18 102.96 ± 5.18 83.08 ± 10.47 87.59 ± 11.64 86.95 ± 3.43
pCREB 99.99 ± 0.14 137.2 ± 6.15* 101.94 ± 4.66# 134.16 ± 4.45* 101.33 ± 3.11#
pNF-κB 99.94 ± 0.27 102.36 ± 3.44 105.52 ± 5.81 108.63 ± 5.65 97.12 ± 7.78
Hypo TRPV1 100.29 ± 0.30 149.64 ± 4.75* 95.76 ± 3.73# 154.23 ± 3.62* 26.63 ± 1.06*#
pPKA 99.66 ± 0.31 134.21 ± 6.86* 93.72 ± 2.82# 134.42 ± 11.03* 97.37 ± 5.69#
pPI3K 99.98 ± 0.13 149.33 ± 10.77* 107.09 ± 2.82# 151.50 ± 9.49* 105.61 ± 3.86#
pPKC 99.80 ± 0.22 135.23 ± 7.79* 99.99 ± 0.78# 126.46 ± 5.61* 96.50 ± 3.89#
pERK 99.94 ± 0.36 139.68 ± 1.61* 91.10 ± 4.01# 127.05 ± 1.86* 91.93 ± 4.50#
pP38 100.09 ± 0.32 136.36 ± 5.23* 106.08 ± 3.30# 130.19 ± 8.19* 90.82 ± 7.88#
pJNK 99.77 ± 0.21 147.87 ± 9.57* 101.03 ± 5.02# 143.79 ± 6.08* 101.47 ± 4.74#
pAkt 100.20 ± 0.34 135.58 ± 10.87* 90.54 ± 2.48# 140.86 ± 11.44* 94.64 ± 6.46#
pmTOR 100.31 ± 0.35 143.00 ± 6.88* 97.94 ± 1.94# 149.22 ± 3.99* 101.44 ± 4.92#
pCREB 107.32 ± 7.24 144.19 ± 18.97* 107.18 ± 18.96# 145.45 ± 23.14* 102.35 ± 16.66#
pNF-κB 99.84 ± 0.13 146.15 ± 6.64* 101.33 ± 7.22# 142.00 ± 9.09* 91.07 ± 3.81#
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated